TES-1025

Research use only, not for human use.

TES-1025 is an effective and selective inhibitor of human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (IC50: 13 nM).

TES-1025 is an effective and selective inhibitor of human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (IC50: 13 nM).(In Vitro):TES-1025 increases NAD+ levels in cellular systems.(In Vivo):TES-1025 (0.5 mg/kg; i.v.) shows low blood clearance, with low volumes of distribution and half-lives of about 5.33 h, although the blood concentration of TES-1025 (5 mg/kg) is quantifiable for up to 8 h after oral administration. A good systemic exposure is recorded for TES-1025, with a Cmax of 2570 ng/mL reaches at 2 h. The greater oral exposure of TES-1025 is AUC0-8h of 19?200 h?ng/mL and 36?600 h?ng/mL, respectively.

TES-1025 is a low nanomolar human ACMSD inhibitor, which increases NAD+ levels in cellular systems.

TES-1025 is subjected to in vivo pharmacokinetic studies, following intravenous (IV) and oral (PO) dosings of male CD-1 mice.After the intravenous administration of 0.5 mg/kg, TES-1025 shows low blood clearance, with low volumes of distribution and half-lives (t1/2) of about 5.33 h, although after oral administration at 5 mg/kg, the blood concentration of TES-1025 is quantifiable for up to 8 h. A good systemic exposure is recorded for TES-1025, with a Cmax of 2570 ng/mL reaches at 2 h after dosing. The greater oral exposure of TES-1025 is further confirmed in the liver and kidneys with AUC0-8h of 19?200 h?ng/mL and 36?600 h?ng/mL, respectively.

——

Others

Other Targets

SGLT2

——

——

1883602-21-8

383.44

C18H13N3O3S2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (260.80 mM)

OC(=O)Cc1cccc(CSc2nc(-c3cccs3)c(C#N)c(=O)[nH]2)c1

——

(-20℃)

With Ice Pack

≥ 2 years